LB Pharmaceuticals Inc

15.65-0.92 (-5.55%)

Oct 29, 4:00:01 PM EDT · NasdaqGM · LBRX · USD

Upcoming Earnings

Report date

≈ -

Key Stats

Market Cap

351.23M

P/E (TTM)

Basic EPS (TTM)

-8.31

Dividend Yield

Recent Filings

8-K

IPO governance updates filed

9/12/25Sep 12, 2025

LB Pharmaceuticals Inc. amended and restated its certificate of incorporation and bylaws effective September 12, 2025, coinciding with its IPO closing. These updates, approved by the board and stockholders beforehand, align governance with public company standards. No specific financial impacts disclosed. Standard move for new listings.

About

LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 1 clinical trial for the treatment of bipolar I depression; and in pr clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.

CEO

Ms. Heather D. Turner J.D.

IPO

9/11/2025

Website

https://lbpharma.us

Employees

Sector

Healthcare

Industry

Biotechnology